Thursday 19 January 2017 12:51am
We’re looking for males and females aged 60-80 to participate in a vaccine clinical drug study for Respiratory Syncytial Virus.
RSV is known to cause respiratory disease at any age and infections may be severe among those with health issues. The elderly population are particularly at risk, especially during winter and early spring and currently there is no vaccine available.
The study runs over a 13 month period (visits only) and participants will be paid for their time.
The study has been approved by the Bellberry Human Research Ethics Committee.
Call CMAX on 1800 150 433 to register your interest today.
1300 275 324
+61 8 8407 5151